234 related articles for article (PubMed ID: 16376813)
1. Multiple sclerosis poses tough drug development challenges.
Senior K
Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
[No Abstract] [Full Text] [Related]
2. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Weissert R
Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
[No Abstract] [Full Text] [Related]
3. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Hecht B
Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
[TBL] [Abstract][Full Text] [Related]
4. [Emerging treatments for multiple sclerosis].
Nau JY
Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
[No Abstract] [Full Text] [Related]
5. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
6. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
7. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Chiba K; Kataoka H
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
[No Abstract] [Full Text] [Related]
8. [New disease-modifying and symptomatic therapies for multiple sclerosis].
Weise G; Buttmann M
MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
[No Abstract] [Full Text] [Related]
9. Multiple sclerosis: new insights and therapeutic progress.
Miller D
Lancet Neurol; 2007 Jan; 6(1):5-6. PubMed ID: 17166789
[No Abstract] [Full Text] [Related]
10. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
11. [Fingolimod - a new immunomodulator].
Friedrich FW; Eschenhagen T
Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
[TBL] [Abstract][Full Text] [Related]
12. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
13. Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
Wise J
BMJ; 2012 Feb; 344():e1360. PubMed ID: 22362460
[No Abstract] [Full Text] [Related]
14. Fingolimod. Mitsubishi Pharma/Novartis.
Dumont FJ
IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod: cardiovascular deaths.
Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515137
[No Abstract] [Full Text] [Related]
16. Avoiding infusion therapy prime benefit of new MS drug.
Morrow T
Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
[No Abstract] [Full Text] [Related]
17. Transforming multiple sclerosis trials into practical reality.
Kieseier BC; Wiendl H
Lancet Neurol; 2011 Jun; 10(6):493-4. PubMed ID: 21571592
[No Abstract] [Full Text] [Related]
18. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
19. [An update on the treatment options for multiple sclerosis].
Niino M
Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
[TBL] [Abstract][Full Text] [Related]
20. [Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Zéphir H
Soins; 2009 Nov; (740):39-41. PubMed ID: 20014532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
